Brain Tumor Clinical Trial
Official title:
Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors
Primary Objectives:
1. Assess whether combined treatment with Levothyroxine and Liothyronine improves learning
and memory.
2. Explore the relationship between T3 treatment and other domains of cognitive function,
quality of life, and mood.
Hypothyroidism causes the body to not be able to produce enough thyroid hormones.
Levothyroxine and liothyronine are synthetic (man-made) hormones that may help treat
hypothyroidism by increasing the metabolism (activity) of cells of all tissues in the body.
The combination treatment, given to patients with hypothyroidism, may help improve normal
body and brain functioning.
Levothyroxine is a man-made type of hormone that is made and released by the thyroid gland
(thyroxine [T4]). Liothyronine is also a man-made type of hormone, but it is made by the
thyroid gland (triiodothyronine [T3]). Both levothyroxine and liothyronine effect different
functions in the body that help regulate (control) the activity and amount of energy that
cells use.
Before you can start treatment on this study, you will have what are called "screening
tests." These tests will help the doctor decide if you are eligible to take part in this
study. You will have your complete medical history recorded. You will have a
neuropsychological evaluation (a series of tests that evaluate how well your brain is
performing). This evaluation includes an interview, and tests will be performed to check
your memory, language, and thinking abilities. You will have a neurological exam performed,
which will include measurement of your weight, height, and performance status (how well you
are able to perform daily activities). This will be done within 14 days before the start of
this study.
You will have blood collected (about 2 tablespoons) for routine laboratory tests (free T4,
total T3) for patients with hypothyroidism. You will also be given 4 questionnaires to fill
out that will ask about your general QoL and changes in your mood. These questionnaires will
take about 20 minutes total to complete.
If you are found to be eligible to take part in this study, you will receive your standard
dose of levothyroxine (after you have your blood collected for laboratory tests and physical
measurements taken) by mouth. You will receive liothyronine by mouth on Day 1 of this study
and then have a neuro-cognitive test ( that evaluates how well your brain is performing).
The dose of liothyronine you receive will depend on the dose of levothyroxine that you are
already on.
Approximately 4 weeks after you start on the treatment, you will be called by a research
data coordinator or research nurse who will ask you questions about any symptoms of
hyperthyroidism that you may be having. This is in case your dose of liothyronine is too
high and may need to be adjusted.
You will be receiving levothyroxine and liothyronine for up to 8 weeks. However, you will be
taken off this study, if your disease gets worse or you experience any intolerable side
effects.
You will be asked to return again to the hospital 8 weeks after your first visit for an
end-of-study visit. You will have another neuropsychological evaluation performed. Blood
(around 2 tablespoons) will again be collected to test the levels of free T4 and total T3 in
your body. You will also have your physical measurements taken. You will receive another
standard dose of levothyroxine. You will have another neurocognitive test performed, and you
will be given 4 more questionnaires to evaluate your QoL and any changes in your mood. The
questionnaires will take about 20 minutes total to complete.
Your participation in this study will be over after your end-of-study visit.
This is an investigational study. Liothyronine and levothyroxine each are approved by the
FDA for hypothyroidism and are commercially available. However, the use of these drugs in
combination is experimental. Up to 26 patients will take part in this study. All will be
enrolled at M. D. Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05023434 -
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
|
||
| Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
| Completed |
NCT02768389 -
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
|
Early Phase 1 | |
| Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT03286335 -
Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
|
N/A | |
| Recruiting |
NCT05968053 -
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
|
||
| Recruiting |
NCT05358340 -
Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions
|
N/A | |
| Terminated |
NCT03276676 -
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
|
Phase 2 | |
| Completed |
NCT02851355 -
Follow-up Survey of Patients Who Were Treated for Medulloblastoma or Primitive Neuroectodermal Tumors of the Central Nervous in Norway
|
||
| Completed |
NCT02713087 -
Vasopressor Effects in Anesthetized Patients
|
Phase 4 | |
| Completed |
NCT02409121 -
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
|
N/A | |
| Completed |
NCT02558569 -
The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block
|
Phase 4 | |
| Terminated |
NCT02674945 -
Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase
|
||
| Withdrawn |
NCT02165995 -
Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery Following Surgery
|
N/A | |
| Completed |
NCT01171469 -
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
|
Phase 1 | |
| Withdrawn |
NCT01202539 -
Real-time Assessment of Frameless Intrafraction Motion
|
||
| Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00760409 -
Differentiating Recurrent Brain Tumor Versus Radiation Injury Using MRI
|
N/A | |
| Completed |
NCT00503204 -
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
|
Phase 1 |